Status:
COMPLETED
Stress-induced Sleep Deficits and a Complementary Therapy
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
University of California, Los Angeles
Conditions:
Insomnia Due to Anxiety and Fear
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The COVID-19 pandemic and social isolation order induced stress/anxiety as well as cellphone dependence. As a result, sleep disruption and mental distress became major health concerns. Gamma-aminobuty...
Eligibility Criteria
Inclusion
- Healthy subjects were recruited in Chengdu and Beijing (city) in China,
- Able and willing to sign informed consent,
- Between 18 -60 years old at time of consent,
- No alcohol, drug, and smoking,
- Not using sleep medication(s) or other psychiatric medications.
Exclusion
- Pregnant or Breastfeeding women,
- Currently taking any medications for sleep,
- Reported naps \> 3 times per week
- History of sleep apnea,
- Current alcohol, drug, and smoking
Key Trial Info
Start Date :
July 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2022
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT05280561
Start Date
July 25 2021
End Date
November 3 2022
Last Update
January 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Furise Group Co
Chengdu, Sichuan, China